Tipifarnib as maintenance therapy did not improve disease-free survival in patients with acute myelogenous leukemia at high risk of relapse: Results of the phase III randomized E2902 trial
Selina M. Luger, Victoria X. Wang, Jacob M. Rowe, Mark R. Litzow, Elisabeth Paietta, Rhett P. Ketterling, Hillard Lazarus, Witold B. Rybka, Michael D. Craig, Judith Karp, Brenda W. Cooper, Adel Z. Makary, Lynne S. Kaminer, Frederick R. Appelbaum, Richard A. Larson, Martin S. Tallman
Dive into the research topics of 'Tipifarnib as maintenance therapy did not improve disease-free survival in patients with acute myelogenous leukemia at high risk of relapse: Results of the phase III randomized E2902 trial'. Together they form a unique fingerprint.